You might like
Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† - Annals of Oncology annalsofoncology.org/article/S0923-…
📢We are proud to announce that the EHA-EMN guidelines for the diagnosis, treatment and follow-up of #MultipleMyeloma are now available online! Huge thanks to Evangelos Terpos for coordinating such outstanding work! 👉nature.com/articles/s4157… @thanosdimop @EHA_Hematology
Nivo-AVD vs BV-AVD in older pts (60+) with #Hodgkin. S1826 data. 99 eligible pts. 2y PFS • 89% Nivo-AVD • 64% BV-AVD 55% discontinued BV, 14% Nivo NRM 16% BV-AVD, 6% Nivo-AVD Transformational. If only we had access! #lymsm ascopubs.org/doi/10.1200/JC…
@tobyeyre82 on treatment options in R/R MCL exposed in 1L to BtKi. Time limites exposure to BTKi allows for reexposure at 1st relapse (+/- venetoclax) #18icml #icml2025
Lewis et al - MRD analysis in ENRICH: IR vs R-chemo in 1L MCL • flow cytometry based • MRD- most rapid with BR • with RCHOP, even MRD- pts do poorly • with IR, no assocn with MRD & outcome #18ICML #ICML25 #lymsm
Patel: JNJ4496 (anti CD19/20 tandem CAR) RR DLBCL, 41BB costim • global Ph 1B • med age 72y • at RP2D, ORR 100%, CRR 80% • no G3+ CRS, 8% ICANs Very impressive results #18ICML #ICML25 #lymsm
Sancho et al - POLARGO. • RGemOx vs Pola-RGemOx R/R DLBCL • 2L+ DLBCL (no ASCT eligible if 2L) • OS primary EP: signif adv 12.5mo vs 19.5mo • PFS & CMR rate better • tox modest - ⬆️ infn & PN • no effect of cell of origin Interesting but ? value if 1L PolaRCHP #18ICML
🚨🚨a 🧵 of AURIGA Study 1/The study aimed to determine if adding daratumumab to standard lenalidomide maintenance would improve outcomes in MRD-positive patients with at least VGPR post-ASCT Phase 3, Randomized, Open-Label Trial: A multicenter study randomizing patients 1:1 to…
Post #ASH24. Active myeloma drugs in one table with mechanism of action. Revised slide. Bookmark! Black font — Approved drugs Blue font — Investigational #ASH24VR
Just out: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma #ASH24 @thanosdimop @NEJM Daratumumab significantly prolongs time to active myeloma and overall survival. Proud to be a lead investigator of this trial nejm.org/doi/full/10.10… Slides in thread
My Annual Updated Myeloma Treatment Algorithms thread. Bookmark! #ASH24 #ASH24VR 1. Newly diagnosed transplant ineligible. Quadruplet unless frail. Maintenance varies by risk stratification.
#Myeloma Paper of the Day: Brazilian study of real-life experience of myeloma (MMyBRAve) finds improvement in outcomes (median OS in transplantation-ineligible and eligible patients of 49 & 93 months), but remaining diagnostic and therapeutic gaps: pubmed.ncbi.nlm.nih.gov/39488485/. #mmsm
Salles et al 5 yr results of POLARIX 1L RCT PolaRCHP vs RCHOP in IPI 2-5 DLBCL 5-year PFS estimates 64.2% vs 59.1% HR 0.78; 95% CI: 0.623-0.980 5-year OS 82.2% vs 79.6% not significant #ASH2024 #lymsm
CONGRESS | #IMS2024 | PRESENTATION Abel Costa @anetoc shares findings from a trial of sonrotoclax + dexamethasone in patients with RRMM harboring t(11;14) mutations (N=32). The ORR was 75% among 24 efficacy-evaluable patients, with a ≥ VGPR of 50%. The combination was well…
R/R T-ALL. Therapeutic approach. - How I treat, blood journal 2023. - ESMO guidelines 2024. - ELNetwork guidelines 2024. - NCCN guidelines 2024. What is the best scheme before the alloSCT (antiCD38, Bortezomib, VEN…) ?
Great presentation by Suzanne Lentzsch on Linvoeltamab on RRMM - ORR 71% ,CRS 46%, and a high PFS (70%) at 12mos - need to see if this holds up - ? Best in class or selection bias- too early to tell
Next generation CAR with novel binding domain! Deep and durable response in high risk patients! Look forward to getting this to our patients! @MCWCancerCenter @EHA_Hematology #eha2024
Guideline paradigms in EMD @JHillengass at #IMWG2024. @Myeloma_Society #mmsm
Check out our poster at #EHA2024 with safety and efficacy data from the Ph 1/2 study with Golcadomide +/- Ritux for R/R FL @GuiperiniMD
United States Trends
- 1. Massie 88.6K posts
- 2. #Varanasi 124K posts
- 3. #CollegeGameDay 1,725 posts
- 4. Good Saturday 34.7K posts
- 5. Lawson Luckie N/A
- 6. #MeAndTheeSeriesEP1 1.29M posts
- 7. Willie Green 4,544 posts
- 8. #Caturday 4,595 posts
- 9. #SaturdayVibes 5,091 posts
- 10. Todd Snider N/A
- 11. Virginia Tech 2,284 posts
- 12. Brooklynn 3,351 posts
- 13. James Borrego 1,629 posts
- 14. Draymond 30.1K posts
- 15. Marjorie 110K posts
- 16. Senior Day 2,616 posts
- 17. PONDPHUWIN AT MAT PREMIERE 816K posts
- 18. Lindsey Graham 20.3K posts
- 19. James Franklin 2,003 posts
- 20. Tony Dorsett N/A
You might like
-
Carlos Chiattone
@CarlosChiattone -
Wellington Fernandes
@wellingtonhemat -
Mariana Guarana
@mariana_guarana -
Lucas Cantadori
@lucascantadori -
Isabela
@isaisabelagap -
Jacques Kaufman
@jacqueskaufman -
Guilherme Perini, MD
@GuiperiniMD -
Thiago Carneiro
@thiagoxcarneiro -
Lucila Kerbauy
@lucila_kerbauy -
Madson de Farias
@madsoncdefarias -
Renato Cunha, M.D.-Ph.D.
@DrRenatoCunha -
Vinícius Molla
@viniciusmolla -
The Fellow On Call
@TheFellowOnCall
Something went wrong.
Something went wrong.